Immunological gene therapy approaches for malignant melanoma

Skin Pharmacology and Physiology

Volumn 10, Issue 3, 1997, Pages 105-125

  Bonnekoh, Bernd ^a,b   Bickenbach, Jackie R ^a   Roop, Dennis R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Adenovirus; Cancer; Granulocyte macrophage colony stimulating factor; Interleukin 2; Tumor vaccine

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; MELANOMA VACCINE; MEMBRANE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENOVIRUS; ADOPTIVE TRANSFER; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; GENE AMPLIFICATION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; IMMUNOGENETICS; IMMUNOTHERAPY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INTERLEUKINS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA;

EID: 0030823257     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000211476     Document Type: Article

References (93)

1. Bonnekoh B, Bickenbach JR, Roop DR: Immunological gene therapy approaches for malignant melanoma, 1. Tumor-immunological background, Skin Pharmacol 1997; 10: 49-62.
2. Recombinant DNA Advisory Committee: Human gene marker/therapy clinical protocols, Hum Gene Ther 1996;7:567-588.
3. Anderson WF: End-of-the-year potpourri - 1995. Hum Gene Ther 1995;6:1505-1506.
4. Fcaron ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstcin B, Frost P: Interlcukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response, Cell 1990:60:397-403.
5. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA: Antigen-specific tumor vaccines - Development and characterization of recombinant adenoviruses encoding MARTI or gplOO for cancer therapy, J Immunol 1996; 156:700-710.
6. Nabel GJ, Nabel EG, Yang Z-Y, Fox B, Plautz GE, Gao X, Huang I, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans, Proc Natl Acad Sci USA 1993;90:11307-11311.
7. Tahara H, Lotzc MT: IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts, Hum Gene Ther 1995;6:1607-1624.
8. Hwu P, Rosenberg SA: Gene therapy using lymphocyte modification: in DcVita VT, Heilman S, Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia, Lippin-cott, 1995. pp 727-737.
9. Chang AE: Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene, Hum Gene Ther 1996;7:773-792.
10. Rankin EM: Scientific aspects of gene therapy in melanoma, Curr Opin Oncol 1995:7:192-196.
11. Berd D, Maguire HC, McCue P, Mastrangelo MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients, J Clin Oncol 1990:8:1858-1867.
12. Stingl G: Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene, Hum Gene Ther 1996:7:551-563.
13. Mertelsmann R, Lindemann A, Bochn T, Brcnnschcidt U, Frankc B, Kulmburg P, Lahn M, Mackensen A, Rosenthal FM, Veelken H: Pilot study for the evaluation of T-ccll-mediatcd tumor immunotherapy by cytokine gene transfer in patients with malignant tumors, J Mol Med 1995;73:205-206.
14. Gansbacher B: A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma, Hum Gene Ther 1992;3:677-690.
15. Osanlo S: Immunization with interleukin-2 transfected melanoma cells, A phase 1-11 study in patients with metastatic melanoma, Hum Gene Ther 1993:4:323-330.
16. Lotze MT, Rubin JT: Gene therapy of cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response, Hum Gene Ther 1994;5:41-55.
17. Sumiami Y, Elder EM, Lotze MT, Whiteside TL: In situ inlerleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine, J Immunother 1995; 17:238-248.
18. Elder EM, Lotze MT, Whiteside TL: Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic ther-pay of patients with cancer, Hum Gene Ther 1996:7:479-487.
19. Cascinelli N, Foil R, Parmiani G: Active immunization of metastatic melanoma patients with intcrlcu-kin-4 transduced, allogeneic melanoma cells, A phase l-II study, Hum Gene Ther 1994:5:1059-1064.
20. Mackiewicz A: Gene therapy of human melanoma, Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor, Hum Gene Ther 1995;6:805-811.
21. Schadcndorf D, Czarnctzki BM, Wittig B: Interleukin-7. intcrlcukin-12. and GM-CSF gene transfer in patients with metastatic melanoma, J Mol Med 1995:73:473-477.
22. Schmidt-Wolf IGH, Huhn D, Neu-baued A, Wittig B: Interlcukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma, Hum Gene Ther 1994;5: 1161-1168.
23. Seigler HF, Darrow TL, Abdel-Wa-hab Z, Gangavalli R, Barber J: A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma, Hum Gene Ther 1994:5:761-777.
24. Fenton RT, Sznol M: A phase I trial of B7-transfccted or parental lethal-ly irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or 11LA-A1 in patientswith stage IV melanoma, Hum Gene Ther 1995:6:87-106.
25. Lotze MT, Zch HJ, Elder EM, Cai Q, Pippin BA, Rosenstein MM, Whiteside TL, Herberman R: Use of T-cell growth factors (interleukin 2. 4.7.10. and 12) in the evaluation of T-cell reactivity to melanoma, J Immunother 1992; 12:212-217.
26. Gansbacher B, Zicr K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, Gilboa E, Golde D: Retroviral gene transfer induced constitutive expression of interleukin-2 or intcrferon-y in irradiated human melanoma cells, Blood 1992; 80:2817-2825.
27. Janssen RAJ, Mulder NH, The TH, de Leij L: The immunobiological effects of interleukin-2 in vivo, Cancer Immunol Immunother 1994:39: 207-216.
28. Dalglcish AO: The role of IL-2 in gene therapy, Gene Ther 1994; 1:83-87.
29. Rosenberg SA: The immunotherapy and gene therapy of cancer, J Clin Oncol 1992;10:180-199.
30. Rosenberg SA, Yang JC, Topalian SL, Schwartzcnlrubcr DJ, Weber JS, Parkinson DR, Scipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dosc bolus interleukin 2. J Am Med Assoc 1994;271:907-913.
31. Rosenberg SA, Yannclli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Scipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994:86: 1159-1166.
32. Ett inghausen SE, Rosenberg SA: I m-munotherapy and gene therapy of cancer, Adv Surg 1995:28:223-254.
33. Sznol M, Parkinson DR: Clinical applical ions of 11.-2. Oncology 1994; 8:61-75.
34. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy, Annu Rev Immunol 1995:13:399-415.
35. Zatloukal K, Schneebergcr A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G, Bim-sticl ML: Elicitation of a systemic and protective anti-melanoma immune response by an IL-2 based vaccine: Assessment of critical cellular and molecular parameters, J Immunol 1995:154:3406-3419.
36. JalTec EM, Hurwilz H, Pardoll DM: Gene modification of tumors: in DeVita VT, Heilman S, Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia, Lippincott, 1995. pp 774-783.
37. Zicr KS, Gansbacher B: IL-2 gene therapy of solid tumors: An approach for the prevention of signal transduction defects in T cells, J Mol Med 1996:74:127-134.
38. Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN: Rejection of mouse melanoma elicited by local secretion of interleukin-2: Implicating macrophages without T cells or natural killer cells in tumor rejection, Ini J Cancer 1995;61:253-260.
39. Huang AYC, Golumbek P, Ahmad-zadeh M, Jaffec E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class l-restricted tumor antigens, Science 1994;264:961-965.
40. Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Long-ley MA, Chen S-H, Woo SLC, Roop DR: Inhibition of melanoma growth by adenoviral-mcdiated HSV thymidine kinase gene transfer in vivo, J Invest Dermatol 1995; 104:313-317.
41. Bonnekoh B, Greenhalgh DA, Bundman DS, Kosai K, Chen S-H, Finegold MJ, Krieg T, Woo SLC, Roop DR: Adcnoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma, J Invest Dermatol 1996:106: 1163-1168.
42. Haddada H, Ragot T, Cordier L, Duffour MT, Perricaudet M: Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tu-morigenicity and induces antitumo-ral immunity in mice, Hum Gene Ther 1993;4:703-711.
43. Tahara H, Zeh HJ III, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SE, Robbins PD, Lotze MT: Fibroblasts genet ically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo, Cancer Res 1994;54:182-189.
44. Ohira T, Ohe Y, Heike Y, Podack ER, Olsen KJ, Nishio K, Nishio M, Miyahara Y, Funayama Y, Ogasa-wara H, Arioka H, Kunikane H, Fu-kuda M, Kato H, Saijo N: In vitro and in vivo growth ofB16FI0 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant, Cancer Res Clin Oncol 1994;120:631-635.
45. Marcus SG, Pcrry-Lallev D, Mule JJ, Rosenberg SA, Yang JC: The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity, J Immunother 1994:15:105-112.
46. Armslrong CA, Murray N, Kennedy M, Koppula SV, Tara D, Ansel JC: Melanoma-derived interleukin 6 inhibits in vivo melanoma growth, J Invest Dermatol 1994; 102:278-284.
47. Hock H, Dorsch M, Diamantstein T, Blankcnstcin T: Interleukin 7 induces CD4' T cell-dependent tumor rejection, J Exp Med 1991:174: 1291-1298.
48. Topalian SL: MHC class II restricted tumor antigens and the role of CD4* T cells in cancer immunotherapy, Curr Opin Immunol 1994; 6:741-745.
49. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C, Ferrone S: lmmunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct mono-morphic determinants of HLA antigens, Cancer Res 1984:44:3930-3935.
50. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG: Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dcpendenl mechanism, Cancer Res 1993:53:2112-2117.
51. Gerard CM, Bruvns C, Delvaux A, Baudson N, Dargent J-L, Goldman M, Velu T: Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells, Hum Gene Ther 1996:7:23-31.
52. Bruyns C, Gerard C, Velu T:Cancer escape from immune surveillance: How can it be overcome by gene transfer? Eur J Cancer 1994;30A: 1176-1181.
53. Howard B, Burrascano M, McCal-listcr T, Chong K, Gangavalli R, Severinsson L, Jolly DJ, Darrow T, Vcrvaert C, Abdel-Wahab Z, Siegler HF, Barber JR: Retrovirus-mediated gene transfer of the human y-IFN gene: A therapy for cancer, Ann NY Acad Sci 1994:716:167-187.
54. Ogasawara M, Rosenberg SA: Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with y-intcrfcron genes, Cancer Res 1993;53:3561-3568.
55. Rosenberg SA: Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor, Hum Gene Thcr 1992;3:57-73.
56. Koshita Y, Itoh Y, Fujii S, Neda H, Takahashi M, Watanabc N, Kohgo Y, Niitsu Y: Mechanism of tumor regression of TNF gene-transduced Mcth-A cells transplanted in mice, Ann NY Acad Sci 1994:716:334-335.
57. Tepper RI, Mule JJ: Experimental and clinical studies of cvtokinc gene-modified tumor cells, Hum Gene Ther 1994:5:153-164.
58. Quin Z, Kruger-Krasagakes S, Kun-zendorf U, Hock H, Diamantstein T, Blankenstein T: Expression of tumor necrosis factor by different tumor cell lines results in tumor suppression or augmented metastasis, J Exp Med 1993;178:355-360.
59. Dranot TG, Jaffee E, Lazenby A, Go-lumbek F, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macro-phage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc Natl Acad Sci USA 1993:90:3539-3543.
60. Jones TC: The effects of rhGM-CSE on macrophage function, Eur J Cancer 1993;29A(suppl 3):S10-S13.
61. Rock KL: A new foreign policy: MHC class 1 molecules monitor the outside of the world, Immunol Today 1996;17:131-137.
62. Qin HX, Chatterjee SK: Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine, Gene Thcr 1996:3: 59-66.
63. Hart IR, Vile RG: Targeted gene therapy, Br Med Bull 1995:51:647-655.
64. Allison JP, Hurwitz AA, Leach DR: Manipulation of costimulatory signals to enhance antitumor T-cell response, CurrOpin Immunol 1995:7: 682-686.
65. Wu T-C, Huang AYC, Jaffee EM, Ixtvitsky HI, Pardoll DM: A reassessment of the role of B7-1 expression in tumor rejection, J Exp Med 1995;182:1415-1421.
66. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI: DoesB7-l expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996;183:769-776.
67. Primus FJ, Finch MD, Wetzel SA, Masci AM, Schlont J, Kashmir SVS: Monoclonal antibody gene transfer, Ann NY Acad Sci 1994:716:154-166.
68. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Rcstifo NP: Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen, J Immunol 1996:156:224-231.
69. Irvine KR, Rao JB, Rosenberg SA, Reslifo NP: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary mctastases, J Immunol 1996; 156:238-245.
70. Pardoll DM, Beckcrleg AM: Exposing the immunology of naked DNA vaccines, Immunity 1995.3:165-169.
71. Alijagic S, Moller P, Artuc M, Jur-govsky K, Czametzki BM, Schaden-dorf D: Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation, Eur J Immunol 1995;25:3100-3107.
72. Kim TS, Cohen EP: lnterlcukin-2-sccreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma, Cancer Res 1994:54:2531-2535.
73. Kim TS, Cohen EP: Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secret ion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells, J Immunother 1994:16:24-35.
74. Kim TS, Cohen EP: MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for inlerleukin-2 secretion and the expression of melanoma-associated antigens, Cancer Immunol Immunother 1994;38:185-193.
75. Nabel GJ, Nabel EG: Gene therapy by direct gene transfer, in DeVita VT, Heilman S, Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia, Lippincott, 1995. pp 750-758.
76. Nabel GJ: Immunotherapy for cancer by direct gene trasnfcr into tumors, Hum Gene Ther 1994:5:57-77.
77. Nabel EG, Yang Z, Muller D, Chang AE, Gao X, Huang L, Cho KJ, Na-bel GJ: Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma, Hum Gene Ther 1994:5:1089-1094.
78. Tahara H, Lotze MT: Antitumor effects of interleukin-12 (IL-12): Applications for the immunotherapy and gene therapy of cancer, Gene Thcr 1995;2:96-106.
79. Bonnekoh B, Grcenhalgh DA, Chen S-H, Rich SS, Woo SLC, Roop DR: Adenoviral-mediatcd combination gene therapy for treatment of experimental malignant melanoma in vivo, J Invest Dermatol 1995; 104: 597.
80. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldic J, Graham FL: Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model, Proc Natl Acad Sci USA I995;92:8522-8526.
81. Cordier L, Duffour M-T, Sabourin J-C, Lee MG, Cabannes J, Ragot T, Perricaudct M, Haddada H: Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene, Gene Ther 1995:2:16-21.
82. Rosenberg SA: Gene therapy of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene coding for tumor necrosis factor, Hum Gene Thcr 1990;1:441-480.
83. Tolstoshcv P, Anderson WF: Gene therpay of cancer - Basic principles and safety considerations; in DeVita VT, Heilman S, Rosenberg SA (eds): Biology Therapy of Cancer, ed 2. Philadelphia, Lippincott, 1995. pp 713-726.
84. Hwu P, Yang JC, Cowherd R, Treis-man J, Shafer GE, Eshhar Z, Rosenberg SA: In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes, Cancer Res 1995;55:3369-3373.
85. Wahl WL, Strome SE, Nabel GJ, Plautz GE, Cameron MJ, San H, Fox BA, Shu S, Chang AE: Generation of therapeutic T-lymphocytcs after in vivo tumor transfect ion with an allogeneic class I major histocompatibility complex gene, J Immu-nother 1995;17:1-11.
86. Krauss JC, Strome SE, Chang AE, Shu S: Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J Irnntu-nother 1994; 16:77-84.
87. Rosenberg SA: Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 1992;3:75-90.
88. Golumbck PT, Azhari R, JafTec EM, Levitsky HI, Lazcnby A, Leong K, Pardoll DM: Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design, Cancer Res 1993:53:5841-5844.
89. Blankcnstcin T: Increasing tumor immunogenicity by genetic modification, Eur J Cancer 1994;30A: 1182-1187.
90. Boon T: Tumor antigens and perspectives for cancer immunotherapy, Immunologist 1995;3:262-263.
91. Bonnekoh B, Bickenbach JR, Roop DR: Gene therapy approaches for malignant melanoma - Treatment strategies and therapeutic potential of adenovirus-mediated gene transfer, Proc Am Acad Physicians (submitted).
92. Hart IR, Vile RG: Targeted therapy for malignant melanoma, CurrOpin Oncol 1994;6:221-225.
93. Vile R, Miller N, Chemajovsky Y, Hart I: A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcritpional-ly targeted expression of the HSVtk or IL-2 genes, Gene Ther 1994:1: 307-316.